Comparative Pharmacology
Head-to-head clinical analysis: KETOROLAC TROMETHAMINE versus LODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOROLAC TROMETHAMINE versus LODINE.
KETOROLAC TROMETHAMINE vs LODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing pain and inflammation.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
10 mg orally every 4-6 hours, not to exceed 40 mg per day; or 15-30 mg intramuscularly or intravenously every 6 hours, not to exceed 120 mg per day (maximum 60 mg for single dose).
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
Terminal half-life is 5-6 hours in young adults, prolonged to 9-10 hours in elderly patients (≥65 years) and up to 12-15 hours in renal impairment (CrCl <30 mL/min). Context: q6h dosing interval recommended; accumulation risk in elderly/renal impairment.
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Primarily renal excretion: ~92% of dose excreted in urine as parent drug (60%) and metabolites (p-hydroxyketorolac, conjugated forms). Fecal excretion accounts for ~6%. Biliary excretion is minimal.
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Category D/X
Category C
NSAID
NSAID